Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease : known knowns and known unknowns
Copyright © 2023 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. All rights reserved..
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Kidney international - 105(2024), 4 vom: 22. März, Seite 684-701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levin, Adeera [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CKD |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.kint.2023.10.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370088093 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370088093 | ||
| 003 | DE-627 | ||
| 005 | 20240325235549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.kint.2023.10.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1347.xml |
| 035 | |a (DE-627)NLM370088093 | ||
| 035 | |a (NLM)38519239 | ||
| 035 | |a (PII)S0085-2538(23)00764-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levin, Adeera |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease |b known knowns and known unknowns |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a KDIGO | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a evaluation | |
| 650 | 4 | |a guideline | |
| 650 | 4 | |a management | |
| 700 | 1 | |a Ahmed, Sofia B |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero, Juan Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Rasheeda K |e verfasserin |4 aut | |
| 700 | 1 | |a Herrington, Will G |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Inker, Lesley A |e verfasserin |4 aut | |
| 700 | 1 | |a Kazancıoğlu, Rümeyza |e verfasserin |4 aut | |
| 700 | 1 | |a Lamb, Edmund |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Madero, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Morrow, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Glenda |e verfasserin |4 aut | |
| 700 | 1 | |a Sabanayagam, Dharshana |e verfasserin |4 aut | |
| 700 | 1 | |a Schaeffner, Elke |e verfasserin |4 aut | |
| 700 | 1 | |a Shlipak, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shroff, Rukshana |e verfasserin |4 aut | |
| 700 | 1 | |a Tangri, Navdeep |e verfasserin |4 aut | |
| 700 | 1 | |a Thanachayanont, Teerawat |e verfasserin |4 aut | |
| 700 | 1 | |a Ulasi, Ifeoma |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Germaine |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chih-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Luxia |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Karen A |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Renee F |e verfasserin |4 aut | |
| 700 | 1 | |a Kasiske, Bertram L |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Earley, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens, Paul E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international |d 1972 |g 105(2024), 4 vom: 22. März, Seite 684-701 |w (DE-627)NLM000007188 |x 1523-1755 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2024 |g number:4 |g day:22 |g month:03 |g pages:684-701 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kint.2023.10.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2024 |e 4 |b 22 |c 03 |h 684-701 | ||